eMedicine Specialties > Pediatrics: General Medicine > Infectious Disease

Naegleria

Author: Nicholas John Bennett, MBBCh, PhD, Staff Physician, Department of Pediatrics, State University of New York Upstate Medical University
Coauthor(s): Joseph Domachowske, MD, Associate Professor, Department of Pediatrics, Division of Infectious Diseases, State University of New York-Upstate Medical University; Asad A Khan, MD, Fellow, Department of Internal Medicine, Division of Infectious Diseases, Louisiana State University Health Science Center; John W King, MD, Professor of Medicine, Section of Infectious Diseases, Louisiana State University Health Sciences Center; Director, Viral Therapeutics Clinics for Hepatitis; Consulting Staff, Department of Infectious Diseases, Overton Brook Veterans Affairs Medical Center; J Thomas Cross, Jr, MD, MPH, Vice President, Education, MedStudy Corporation
Contributor Information and Disclosures

Updated: Mar 7, 2008

Introduction

Background

Naegleria fowleri is a ubiquitous free-living ameba that is the etiologic agent in primary amebic meningoencephalitis (PAM). Although N fowleri rarely causes disease, it is important because diagnosis can be difficult and PAM is rapidly fatal in more than 95% of cases. In the summer of 2007, 6 fatal cases of N fowleri infection occurred in the United States, all young males.

The earliest known case of N fowleri –associated disease dates back to 1937 and occurred in a patient from Virginia; however, this case was not reported until 1968, when Dos Santos identified the patient during a retrospective review of autopsies. In 1965, Fowler and Carter published the first report of N fowleri –associated CNS disease.1 In this initial report of 4 patients in Australia, the authors suggested the etiologic amebae probably belonged to the genus Acanthamoeba; however, subsequent investigation shows these cases were most likely due to N fowleri. Acanthamoeba infections tend to progress slower than N fowleri infections, with insidious symptoms that present weeks or months after exposure; these symptoms are more similar to the presentation of a bacterial brain abscess or tumor than to N fowleri infection.

In 1966, Butt reported the first case of N fowleri meningoencephalitis in the United States and coined the term PAM.2 The term was chosen to distinguish the disease caused by N fowleri from the secondary meningoencephalitis due to the extension of Entamoeba histolytica from another site.

N fowleri is a member of the subphylum Sarcodina, superclass Rhizopodea. Rhizopodea includes the free-living amebae Entamoeba histolytica and species of Acanthamoeba, Hartmannella, Balamuthia, Naegleria, and others. Although N fowleri is one of several species in the genus Naegleria, to date, it remains the only Naegleria species known to produce human disease.

Most N fowleri infections have occurred in children and young adults who have had recent exposure to swimming or diving in warm freshwater.3 The thermophilic nature of N fowleri allows it to survive in waterways contaminated by thermal discharges from power plants, heated swimming pools, and even hot springs with temperatures up to 45°C (113°F). Most cases of PAM occur during the summer months, when freshwater sources are warm. When water temperatures decrease, N fowleri encyst and enter a dormant stage, which allows them to survive until the next summer.

Pathophysiology

The events that lead to N fowleri –associated PAM usually result from swimming or diving in warm water contaminated with N fowleri. The N fowleri trophozoites enter the nose and invade the olfactory mucosa, penetrate the submucosal nervous plexus, cross the cribriform plate, and gain access to the subarachnoid space. The presence of protein and glucose in the cerebrospinal fluid (CSF) supports the growth of amebae, which then multiply rapidly and invade the parenchyma of the brain. Because N fowleri possess mitochondria, the high oxygen content of the brain and CSF enhance its growth.

The invasive trophozoites are highly phagocytic and ingest RBCs and brain tissue, resulting in severe hemorrhagic necrosis of the involved brain. Brain tissue, unlike RBCs, cannot be ingested whole by the trophozoites; however, N fowleri produces an amebostome, or food cup, into which it secretes lysosomal hydrolases and phospholipases. N fowleri can also use heat-stable hemolytic proteins, heat-labile cytolysin, phospholipase A, and a cysteine protease to kill cells in contact with the trophozoites. In 2000, Chu et al demonstrated that normal human serum is capable of activating protein kinases with subsequent protein phosphorylation, which results in enhanced complement resistance in N fowleri.4

N fowleri produces a diffuse hemorrhagic meningoencephalitis associated with purulent meningitis. The cortical gray matter is the most severely involved area. Because of severe edema of the brain, CSF pressures are elevated, and uncal or cerebellar herniation can occur.

Apart from the damage to the CNS, infection with N fowleri is also associated with a neutrophilic myocarditis; however, amebic trophozoites are not present in the myocardium. The clinical significance of this myocarditis is unknown.

The life cycle of N fowleri has 3 stages.

  1. Trophozoite (vegetative) stage: The trophozoite is the reproductive stage of the protozoan. The trophozoite measures 10-30 µm in diameter and is characterized by a nucleus with a large centrally placed karyosome with a surrounding halo. Trophozoites are motile and move by extending a blunt lobopodium (pseudopodium) and allowing the cell cytoplasm and contents to flow into the extension. Lobopodia form at different points along the cell surface, allowing the trophozoite to change direction. In their free state, trophozoites feed on bacteria and exhibit aerobic metabolism via their mitochondria. In tissue, trophozoites phagocytize RBCs and WBCs and destroy tissue with which they come into contact. Trophozoites replicate by binary fission, which occurs only in this stage.
  2. Flagellate stage: When the N fowleri trophozoites are exposed to a change in ionic concentration, such as placement in distilled water, they transform into pear-shaped biflagellates or multiflagellates.
  3. Cyst stage: Trophozoites encyst in response to unfavorable conditions, such as exposure to cold. The spherical cysts have a single nucleus surrounded by a dense cell wall with 1-2 flat pores, which are plugged with mucus. Cysts range from 7-14 µm.

Frequency

United States

Only 23 cases of N fowleri infection were documented in the United States between 1995 and 2004, but an unusual spike of 6 unrelated cases (all fatal) occurred in the summer of 2007. Cases have been reported along the east coast from Virginia to Florida, as well as in California. Several cases were reported annually in Texas throughout the 1990s. Infection can occur in any situation in which exposure to warm freshwater is present, and geographic location should not be used as a means to rule out infection.

International

N fowleri has a worldwide distribution, but more than one half of reported infections have occurred in the United States. This may reflect a reporting bias because of the difficulty in making the diagnosis. Most human infections occur during the summer months, when recreational water use and water temperatures are highest. Around 200 cases of PAM have been reported worldwide.

Mortality/Morbidity

The mortality rate of N fowleri infections is extremely high. Of more than 200 cases of PAM, only around a dozen people have reportedly survived. The estimated mortality rate is approximately 95%.

Race

N fowleri infection has no known racial predilection.

Sex

The male-to-female ratio is 3:1. This may reflect a greater exposure risk for males rather than a true sexual predisposition to infection.

Age

N fowleri PAM is primarily a disease of children and young adults. The youngest child with PAM described in the literature is a 5-month-old infant.

Breed

Although experimental animals such as rodents, rabbits, and sheep are susceptible to N fowleri infections, only one report has described a naturally acquired infection in an animal, a South American tapir.5

Clinical

History

N fowleri usually occurs in children or young adults who have a history of exposure to swimming or diving in warm freshwater within the last 7-14 days. Most often, the first symptoms develop 2-5 days after the last exposure to contaminated water. The illness begins suddenly with the abrupt onset of fever, headache, nausea, and vomiting. Occasionally, a prodromal stage of altered taste (ie, ageusia) and smell (ie, parosmia) may occur. Altered mental status occurs in about two thirds of patients and is followed by rapid deterioration to coma and death.

Physical

The physical findings in PAM result from rapid spread of N fowleri from the submucosal olfactory nerves through the cribriform plate and into the olfactory bulb. Virtually all patients have meningismus by the time they reach medical care. Patients do not usually develop focal neurologic defects; however, cranial nerve palsies involving III, IV, and V, as well as cerebellar ataxia and reduced deep tendon reflexes, have been reported. Patients often have papilledema and nystagmus. In the final stage just prior to death, the patient may have decerebrate posturing.

Causes

PAM is the term applied to the severe hemorrhagic meningoencephalitis caused by pathogenic strains of N fowleri. N fowleri is the only member of genus Naegleria known to be pathogenic to humans.

More on Naegleria

Overview: Naegleria
Differential Diagnoses & Workup: Naegleria
Treatment & Medication: Naegleria
Follow-up: Naegleria
References

References

  1. Fowler M, Carter RF. Acute pyogenic meningitis probably due to Acanthamoeba sp: a preliminary report. Br Med J. Sep 25 1965;5464:740-2. [Medline].

  2. Butt CG. Primary amebic meningoencephalitis. N Engl J Med. Jun 30 1966;274(26):1473-6. [Medline].

  3. Hebbar S, Bairy I, Bhaskaranand N, et al. Fatal case of Naegleria fowleri meningo-encephalitis in an infant: case report. Ann Trop Paediatr. Sep 2005;25(3):223-6. [Medline].

  4. Chu DM, Ferguson TJ, Marciano-Cabral F. Protein kinase activation and protein phosphorylation in Naegleria fowleri amebae in response to normal human serum. J Eukaryot Microbiol. Jan-Feb 2000;47(1):40-7. [Medline].

  5. Lozano-Alarcon F, Bradley GA, Houser BS, Visvesvara GS. Primary amebic meningoencephalitis due to Naegleria fowleri in a South American tapir. Vet Pathol. May 1997;34(3):239-43. [Medline].

  6. Schuster FL, Visvesvara GS. Free-living amoebae as opportunistic and non-opportunistic pathogens of humans and animals. International Journal for Parasitology. 2004;Vol 34, Issue 9:1001-1027. [Full Text].

  7. Barnett ND, Kaplan AM, Hopkin RJ, et al. Primary amoebic meningoencephalitis with Naegleria fowleri: clinical review. Pediatr Neurol. Oct 1996;15(3):230-4. [Medline].

  8. Anderson K, Jamieson A. Primary amoebic meningoencephalitis. Lancet. Apr 22 1972;1(7756):902-3. [Medline].

  9. Brown RL. Successful treatment of primary amebic meningoencephalitis. Arch Intern Med. Jun 1991;151(6):1201-2. [Medline].

  10. CDC. From the Centers for Disease Control. Primary amebic meningoencephalitis--North Carolina, 1991. JAMA. Aug 19 1992;268(7):862-3. [Medline].

  11. Cerva L. Laboratory diagnosis of primary amoebic meningo-encephalitis and methods for the detection of limax amoebae in the environment. Folia Parasitol (Praha). 1980;27(1):1-9. [Medline].

  12. Committee on Infections Diseases. Amebic meningoencephalitis and keratitis. In: 2006 Report of the Committee on Infections Diseases. 2006:206-8.

  13. DeNapoli TS, Rutman JY, Robinson JR, Rhodes MM. Primary amoebic meningoencephalitis after swimming in the Rio Grande. Tex Med. Oct 1996;92(10):59-63. [Medline].

  14. Dingley D. Safe water practices can lower risk of contracting primary amoebic meningoencephalitis. Tex Med. Oct 1996;92(10):28-9. [Medline].

  15. Dubray BL, Wilhelm WE, Jennings BR. Serology of Naegleria fowleri and Naegleria lovaniensis in a hospital survey. J Protozool. Aug 1987;34(3):322-7. [Medline].

  16. Duma RJ, Rosenblum WI, McGehee RF, et al. Primary amoebic meningoencephalitis caused by Naegleria. Two new cases, response to amphotericin B, and a review. Ann Intern Med. Jun 1971;74(6):923-31. [Medline].

  17. Gustavo dos Santos Neto. Fatal primary amebic meningoencephalitis. A retrospective study in Richmond, Virginia. Am J Clin Pathol. Nov 1970;54(5):737-42. [Medline].

  18. Jarolim KL, McCosh JK, Howard MJ, John DT. A light microscopy study of the migration of Naegleria fowleri from the nasal submucosa to the central nervous system during the early stage of primary amebic meningoencephalitis in mice. J Parasitol. Feb 2000;86(1):50-5. [Medline].

  19. John DT. Primary amebic meningoencephalitis and the biology of Naegleria fowleri. Annu Rev Microbiol. 1982;36:101-23. [Medline].

  20. Kidney DD, Kim SH. CNS infections with free-living amebas: neuroimaging findings. AJR Am J Roentgenol. Sep 1998;171(3):809-12. [Medline].

  21. Lawande RV, Macfarlane JT, Weir WR, Awunor-Renner C. A case of primary amebic meningoencephalitis in a Nigerian farmer. Am J Trop Med Hyg. Jan 1980;29(1):21-5. [Medline].

  22. Levy DA, Bens MS, Craun GF, et al. Surveillance for waterborne-disease outbreaks--United States, 1995-1996. Mor Mortal Wkly Rep CDC Surveill Summ. Dec 11 1998;47(5):1-34. [Medline].

  23. Loschiavo F, Ventura-Spagnolo T, Sessa E, Bramanti P. Acute primary meningoencephalitis from entamoeba Naegleria Fowleri. Report of a clinical case with a favourable outcome. Acta Neurol (Napoli). Oct 1993;15(5):333-40. [Medline].

  24. Ma P, Visvesvara GS, Martinez AJ, et al. Naegleria and Acanthamoeba infections: review. Rev Infect Dis. May-Jun 1990;12(3):490-513. [Medline].

  25. Markowitz SM, Martinez AJ, Duma RJ, Shiel FO. Myocarditis associated with primary amebic (Naegleria) meningoencephalitis. Am J Clin Pathol. Nov 1974;62(5):619-28. [Medline].

  26. Martinez AJ, Visvesvara GS. Free-living, amphizoic and opportunistic amebas. Brain Pathol. Jan 1997;7(1):583-98. [Medline].

  27. Reilly MF, Marciano-Cabral F, Bradley DW, Bradley SG. Agglutination of Naegleria fowleri and Naegleria gruberi by antibodies in human serum. J Clin Microbiol. Apr 1983;17(4):576-81. [Medline].

  28. Scaglia M, Gatti S, Bernuzzi AM. An in vitro comparative study on the effect of amphotericin B, econazole, and 5-fluorocytosine on Naegleria fowleri, Naegleria australiensis, and Naegleria australiensis s.sp. italica. Microbiologica. Oct 1988;11(4):279-88. [Medline].

  29. Schuster FL, Guglielmo BJ, Visvesvara GS. In-vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: Balamuthia mandrillaris, Acanthamoeba spp., and Naegleria fowleri. J Eukaryot Microbiol. Mar-Apr 2006;53(2):121-6. [Medline].

  30. Seidel JS, Harmatz P, Visvesvara GS, et al. Successful treatment of primary amebic meningoencephalitis. N Engl J Med. Feb 11 1982;306(6):346-8. [Medline].

  31. Shenoy S, Wilson G, Prashanth HV, et al. Primary meningoencephalitis by Naegleria fowleri: first reported case from Mangalore, South India. J Clin Microbiol. Jan 2002;40(1):309-10. [Medline][Full Text].

  32. Stevens AR, Shulman ST, Lansen TA, et al. Primary amoebic meningoencephalitis: a report of two cases and antibiotic and immunologic studies. J Infect Dis. Feb 1981;143(2):193-9. [Medline].

  33. Sugita Y, Fujii T, Hayashi I, et al. Primary amebic meningoencephalitis due to Naegleria fowleri: an autopsy case in Japan. Pathol Int. May 1999;49(5):468-70. [Medline].

  34. Szenasi Z, Endo T, Yagita K, Nagy E. Isolation, identification and increasing importance of ''free-living'' amoebae causing human disease. J Med Microbiol. Jan 1998;47(1):5-16. [Medline].

  35. Valenzuela G, Lopez-Corella E, De Jonckheere JF. Primary amoebic meningoencephalitis in a young male from northwestern Mexico. Trans R Soc Trop Med Hyg. 1984;78(4):558-9. [Medline].

  36. Visvesvara GS, Stehr-Green JK. Epidemiology of free-living ameba infections. J Protozool. Jul-Aug 1990;37(4):25S-33S. [Medline].

Further Reading

Keywords

Naegleria aerobia, N aerobia, Naegleria invadens, N invadens, Naegleria fowleri, N fowleri, primary amebic meningoencephalitis, PAM, hemorrhagic meningoencephalitis, neutrophilic myocarditis, naegleria, meningismus, papilledema, nystagmus, viral encephalitis, meningitis, hyponatremia, hyperglycemia

Contributor Information and Disclosures

Author

Nicholas John Bennett, MBBCh, PhD, Staff Physician, Department of Pediatrics, State University of New York Upstate Medical University
Nicholas John Bennett, MBBCh, PhD is a member of the following medical societies: American Academy of Pediatrics
Disclosure: Nothing to disclose.

Coauthor(s)

Joseph Domachowske, MD, Associate Professor, Department of Pediatrics, Division of Infectious Diseases, State University of New York-Upstate Medical University
Joseph Domachowske, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Society for Microbiology, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, and Phi Beta Kappa
Disclosure: Nothing to disclose.

Asad A Khan, MD, Fellow, Department of Internal Medicine, Division of Infectious Diseases, Louisiana State University Health Science Center
Asad A Khan, MD is a member of the following medical societies: American College of Physicians and Infectious Diseases Society of America
Disclosure: Nothing to disclose.

John W King, MD, Professor of Medicine, Section of Infectious Diseases, Louisiana State University Health Sciences Center; Director, Viral Therapeutics Clinics for Hepatitis; Consulting Staff, Department of Infectious Diseases, Overton Brook Veterans Affairs Medical Center
John W King, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians, American Federation for Medical Research, American Society for Microbiology, Association of Subspecialty Professors, Infectious Diseases Society of America, and Sigma Xi
Disclosure: emedicine $50.00 author of chapter

J Thomas Cross, Jr, MD, MPH, Vice President, Education, MedStudy Corporation
J Thomas Cross, Jr, MD, MPH is a member of the following medical societies: American Academy of Pediatrics, American College of Physicians, Infectious Diseases Society of America, and Pediatric Infectious Diseases Society
Disclosure: Nothing to disclose.

Medical Editor

José Rafael Romero, MD, Director of Pediatric Infectious Diseases Fellowship Program, Associate Professor, Department of Pediatrics, Combined Division of Pediatric Infectious Diseases, Creighton University/University of Nebraska Medical Center
José Rafael Romero, MD is a member of the following medical societies: American Academy of Pediatrics, American Society for Microbiology, Infectious Diseases Society of America, New York Academy of Sciences, and Pediatric Infectious Diseases Society
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine.com, Inc
Disclosure: Pfizer Inc Stock Investment from broker recommendation; Avanir Pharma Stock Investment from broker recommendation

Managing Editor

Joseph Domachowske, MD, Associate Professor, Department of Pediatrics, Division of Infectious Diseases, State University of New York-Upstate Medical University
Joseph Domachowske, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Society for Microbiology, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, and Phi Beta Kappa
Disclosure: Nothing to disclose.

CME Editor

Robert W Tolan Jr, MD, Chief of Allergy, Immunology and Infectious Diseases, The Children's Hospital at Saint Peter's University Hospital; Clinical Associate Professor of Pediatrics, Drexel University College of Medicine
Robert W Tolan Jr, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Society for Microbiology, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, Phi Beta Kappa, and Physicians for Social Responsibility
Disclosure: GlaxoSmithKline Honoraria Speaking and teaching; MedImmune Honoraria Consulting; MedImmune Honoraria Speaking and teaching; Merck Honoraria Speaking and teaching; Novartis Honoraria Speaking and teaching; sanofi pasteur Grant/research funds Unrestricted research grant; sanofi pasteur  Consulting; sanofi pasteur Honoraria Speaking and teaching; Tap Honoraria Speaking and teaching

Chief Editor

Russell W Steele, MD, Head, Division of Pediatric Infectious Diseases, Ochsner Children's Health Center; Clinical Professor, Department of Pediatrics, Tulane University School of Medicine
Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, and Southern Medical Association
Disclosure: None None None

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.